Navigation Links
Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
Date:3/18/2008

CAMBRIDGE, Mass., March 18 /PRNewswire/ -- Peptimmune, Inc. a privately held biotechnology company, announced that it has completed its first clinical trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PI-2301, a novel peptide copolymer for the treatment of multiple sclerosis and other autoimmune diseases.

The Phase I single ascending dose, double blind placebo controlled randomized study involved 56 healthy volunteers who received the drug in eight escalating dose cohorts. All doses were safe and well tolerated, and there were no serious adverse events. Pharmacodynamic assays demonstrated evidence of immune exposure consistent with the pharmacologic mechanism of action for PI-2301, and dose related pharmacokinetics were observed. The Company plans to initiate its first repeat dose study in multiple sclerosis patients in Q2/2008.

"We are pleased to see that PI-2301 was well tolerated and that this trial has provided evidence of single dose priming of healthy subjects. This effect is important as repeated doses in multiple sclerosis patients should lead to therapeutic immune modulation," stated Thomas P. Mathers, President and CEO of Peptimmune. "We have designed PI-2301 to maximize the therapeutic benefit of a proven, safe compound class in multiple sclerosis as well as increasing patients' convenience."

PI-2301 is a second generation peptide copolymer from a similar compound class as Copaxone(R) (Teva Pharmaceuticals). PI-2301 works through immune modulation by enhancing the regulatory response of the immune system to control the pathogenic autoimmune response in certain diseases. PI-2301 has been optimized using Peptimmune's novel platform peptide chemistry and in pre- clinical studies, has shown to be more potent and effective than Copaxone in treating disease models for multiple sclerosis. PI-2301 has also shown efficacy in pre-clinical models of autoimmune diseases where immune modulation may be effe
'/>"/>

SOURCE Peptimmune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Peptimmune Initiates Phase I Study With a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
2. NanoBio Corporation Successfully Completes Phase 2b Study in Herpes Labialis
3. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
4. Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study
5. NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones
6. Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA)
7. MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study
8. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
9. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
10. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
11. Nastech Completes Enrollment of Phase 2 Clinical Trial of PYY3-36 Nasal Spray to Treat Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... , Nov. 24, 2014 Luoxis ... (NYSE MKT: AMPE), today announced the presentation of ... Diagnostic System as a broadly applicable and robust ... in the body in response to injury, illness, ... performed in collaboration with Luoxis, academic and pharmaceutical ...
(Date:11/24/2014)... Nov. 24, 2014 The Female Health Company ... investor conference call to discuss its operating results for ... 2014 on Tuesday, December 2, 2014 at 11:00 a.m. ... its operating results earlier the same day. ... conference call by dialing 1-877-374-8416 (international participants dial 1-412-317-6716) ...
(Date:11/24/2014)... , Nov. 24, 2014  GlySens Incorporated announced ... million dollar grant from the National Institute of Diabetes ... the National Institutes of Health (NIH).  The grant is ... second generation ICGM™ long term implantable glucose monitoring system.  ... and enrollment is expected to begin before the end ...
Breaking Medicine Technology:Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 2Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 3Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 4Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 5The Female Health Company To Report FY2014 Operating Results on Tuesday, December 2, 2014 2GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health 2
... with Durezol Dosed Prior to Surgery, TAMPA, ... held ophthalmic-focused biopharmaceutical company, announced,today that Durezol(TM) (difluprednate ... was approved by the U.S. Food and,Drug Administration ... for the treatment of inflammation and pain associated ...
... MEETING, Pa., Oct. 6 Genaera,Corporation (Nasdaq: GENR ... trial of trodusquemine (MSI-1436), Genaera,s lead drug candidate,for the ... a novel,inhibitor of PTP1B, a validated molecular target that ... to normalize glucose and decrease,appetite. In the study, MSI-1436 ...
Cached Medicine Technology:Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 2Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 3Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 4Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 5Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 2Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 3Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 4
(Date:11/24/2014)... November 24, 2014 Mental health ... day. They break up families, ruin careers, and ... hope for those that suffer,” says Hardy ... is showing that our specialized nutritional treatments can ... appear on “Mind Over Matter”, the premiere episode ...
(Date:11/24/2014)... Gersowitz Libo & Korek, P.C., a leading national ... recognition in the 2015 Edition of U.S. News-Best Lawyers list ... unique combination of quality law practice and breadth of legal ... and especially grateful to our clients whose continued support of ... said Jeff S. Korek, senior partner at Gersowitz Libo ...
(Date:11/23/2014)... a well-known wedding dress manufacturer, has unveiled its new collection ... now offered at deeply discounted prices, up to 75 percent ... 15. The main purpose of the promotion is to expand ... are ideal options for ladies who are eager to look ... new mint cocktail dresses are very beautiful; they are made ...
(Date:11/23/2014)... Pro Ace Care, a renowned Vancouver hot water ... providing an 8 year warranty on its selected hot water ... up due to the impending winter season, it was important ... premium service that the company provides. As a result, Pro ... Wood and Bradford hot water tanks. , “Every installer ...
(Date:11/23/2014)... Locks-Magnetic.com, a notable magnetic locks maker, has released ... products are available at low rates up to 30% ... the new emergency doors. The emergency door adopts fireproof ... from several colors. All of the products are top-quality ... is not as easy as many people think. ...
Breaking Medicine News(10 mins):Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 2Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 3Health News:U.S. News-Best Lawyers “Best Law Firms” Names Gersowitz Libo & Korek P.C. a 2015 Tier 1 Ranking Firm 2Health News:Trendy Long Black Evening Gowns Now Provided By iFitDress.com 2Health News:Pro Ace Care Now Gives 8 Year Guarantee on Selected Vancouver Hot Water Tanks 2
... its patient care and billing like Tesco and Toyota to ... be improved by regularizing the movement of patients from Accident ... ,Services like redesigning, making improvements in healthcare, and giving ... Toyota group of companies, which needs to be copied by ...
... has stated, that it suspects that ‘Pneumonic plague’ is responsible ... according to preliminary test results// that it has conducted. The ... set up to treat patients. They also explained that the ... lack of security ,in the area. ,The outbreak ...
... of postgraduate students at Tshwane University of Technology (TUT) ... inch//. No, this is not revenge on your husband ... method to fight obesity. ,Department of sport ... Andrew McKune said that the group of 40 students ...
... resorted to the strike against OBC reservation in educational institutions, ... // to doctors for the strike period was not a ... no pay. If court orders to release the salaries, we ... to protests by medicos at the AIIMS for not getting ...
... Peace, Vijay Amritraj, has launched a charity that will ... ,The UN estimates that about 5.5 million ... a fraction is getting treatment despite the country's pharmaceutical ... ,Launching the `Amritraj Foundation' yesterday, the 53-year old sportsman, ...
... today said it has allotted 61,716 equity shares upon conversion ... FCCB holders. // ,The committee of directors at ... five each of the company at a premium of Rs ... each, the company informed the Bombay Stock Exchange., ,Consequently, ...
Cached Medicine News:
The Calcitonin ELISA is intended for the quantitative determination of Calcitonin in human serum....
... exclusively distributed by Medtronic, sets the ... intra-operative imaging with surgical navigation in ... is one of the most comprehensive ... Exceptional image quality from a low-field ...
Microwell EIA for detection of Calcitonin...
Mircrowell EIA for detection of Intact PTH...
Medicine Products: